The Economic Costs of Alcohol and Drug Abuse in the United States - 1992
Table 4.20
Treatment Costs per Acute Hepatitis C Virus Case
| Disease Stages/Conditions |
Probability of Stage
(%) |
Number of Cases in 1992 |
Cost per Case in 1992
(dollars) |
Total HCV Treatment Expenditures
(millions of dollars) |
Total IVDU-Related HCV Expenditures
(millions of dollars) |
| Acute Disease Only |
| Subclinical |
65.7 |
111,690 |
$6 |
$0.7 |
$0.3 |
| Clinical, nonfulminant |
34.0 |
57,800 |
$703 |
$40.6 |
$14.6 |
| Fulminant |
0.3 |
510 |
$12,124 |
$6.2 |
$2.2 |
| Subtotal, Acute |
100.0 |
170,000 |
NA |
$47.5 |
$17.1 |
| Chronic Disease |
| Chronic carrier state |
24.9 |
14,420 |
$950 |
$13.7 |
$4.9 |
| Chronic persistent state |
12.5 |
7,239 |
$1,618 |
$11.7 |
$4.2 |
| Chronic active hepatitis |
16.3 |
9,440 |
$67,486 |
$637.1 |
$229.3 |
| Primary hepatic cancer |
8.1 |
4,691 |
$103,148 |
$483.9 |
$174.2 |
| Subtotal, Chronic |
˜50 |
35,790 |
NA |
$1,146.3 |
$412.7 |
| Total, All Conditions |
$1,193.8 |
$429.8 |
Source: Bloom et al. (1993).
Notes: Components may not sum to totals because of rounding. Intravenous drug use is estimated to cause 36 percent of hepatitis C (HCV) cases. Total probability of chronic disease stage (50 percent) is less than the sum of specific categories because more than one category of chronic stage is possible with any given case.
|
